Trump Administration Imposes Up to 100 Percent Tariffs on Patented Pharmaceuticals: The IP Implications of Excluding Generics

On April 2, 2026, the President signed a Proclamation titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” imposing tariffs of up to 100 percent on patented pharmaceutical products. Announced on the first anniversary of so-called “Liberation Day,” the measure invokes national security and domestic manufacturing as its justifications.

Scope of the Measure: What Is Covered and What Is Exempt

According to the White House Fact Sheet, the tariffs are imposed under Section 232 of the Trade Expansion Act of 1962, framed as a national security measure. Covered products include pharmaceutical articles listed in the FDA’s Orange Book (small-molecule drugs) or Purple Book (biological products) that are subject to a valid, unexpired U.S. patent, along with their active pharmaceutical ingredients (APIs) and key starting materials.

Generic drugs, biosimilars, and their related ingredients are currently exempt from the tariffs. However, as ABC News reported, this exemption is set to be reassessed in one year and is not a permanent exclusion.

Additional carve-outs apply to orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates (ADCs), and medical countermeasures, which may receive a 0 percent duty rate upon relevant government findings.

Phased Implementation Timeline

As detailed by Ropes & Gray, the tariffs take effect in two phases. For 17 identified major pharmaceutical companies, the tariffs become effective on July 31, 2026 (120 days after the Proclamation). For all other importers, the effective date is September 29, 2026 (180 days after).

Tariff reduction pathways are available. Companies planning to onshore production face an initial 20 percent tariff rate, rising to 100 percent after four years. According to CNBC, firms that have completed drug pricing deals with the Department of Health and Human Services (HHS), or are currently negotiating while building domestic manufacturing capacity, qualify for exemptions.

Country-specific rates also apply: the EU, Japan, South Korea, and Switzerland face a 15 percent rate, while the UK faces 10 percent.

Patent Status as the Dividing Line: An Unprecedented Structure

From an intellectual property perspective, the most striking feature of this measure is its use of patent status as the criterion for tariff application. Traditionally, tariffs are determined by the physical nature of goods or their HS classification codes. Here, the existence of a valid U.S. patent serves as the basis for taxation.

This structure creates a counterintuitive incentive within the patent system. For patent holders, owning a patent now carries an additional cost in the form of increased tariff exposure. For generic manufacturers, the absence of patent protection on their products translates into a tariff advantage, potentially accelerating market entry following patent expiration.

As Crowell & Moring emphasizes, this marks the first application of Section 232 to pharmaceuticals. Previously reserved for heavy industries such as steel or aluminum, the extension of national security logic to pharmaceutical supply chains sets a new precedent linking intellectual property to trade policy.

Industry Impact

According to Advisory Board, the ultimate impact on drug prices remains uncertain. Patented drugs are already expensive, and a 100 percent tariff could theoretically double their cost. However, if domestic manufacturing transitions and pricing negotiations function as intended, the practical impact may be limited.

The core challenge lies in the global structure of pharmaceutical supply chains. API manufacturing is concentrated in India or China, while formulation often occurs in Ireland, Singapore, or other locations. Choosing domestic manufacturing to avoid 100 percent tariffs requires multi-year capital investments and regulatory approvals.

Assessment from an IP Policy Perspective

On its surface, this measure is a trade policy aimed at reshoring manufacturing. At a deeper level, however, it raises fundamental questions about the function of the patent system.

The patent system is designed to incentivize R&D investment by granting exclusive rights for a limited period. When patent ownership is linked to increased tariff burdens, the cost-benefit calculus of patent acquisition changes. The exemption for generics, meanwhile, can be read as a message that companies enjoying patent-based exclusivity should bear a proportionate burden, essentially leveraging the patent system for manufacturing policy rather than innovation policy.

Looking ahead, key questions include whether the country-specific tariff rates will withstand scrutiny under WTO rules and how discriminatory taxation based on patent status will be debated in relation to the TRIPS Agreement. This measure, standing at the intersection of patent protection and trade policy, may have far-reaching implications for the international IP order.